Trial Profile
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Elagolix (Primary)
- Indications Endometriosis; Pelvic pain
- Focus Therapeutic Use
- Acronyms Elaris EM-III; EM-III
- Sponsors AbbVie
- 06 Jun 2018 Results from two extension studies assessing long terms outcomes of Elagolix in women with Endometriosis (NCT01760954 (n=287) and NCT02143713 (n=282)), published in the Obstetrics and Gynecology Journal.
- 30 Apr 2018 Results presented at the 66th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists
- 30 Apr 2018 Results of pooled data from two phase 3 trials (Elaris EM-III and IV) assessing long-term safety and efficacy of elagolix treatment in women with endometriosis-associated pain, were presented at the 66th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.